Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1966 4
1967 1
1968 2
1969 2
1970 2
1974 1
1975 5
1977 2
1978 1
1979 2
1980 2
1981 4
1982 6
1983 5
1985 2
1986 3
1987 5
1988 2
1989 2
1990 2
1991 2
1992 1
1993 4
1994 2
1995 4
1996 4
1997 4
1998 2
1999 3
2000 5
2001 3
2002 4
2003 5
2004 7
2005 7
2006 3
2007 7
2008 5
2009 9
2010 6
2011 5
2012 11
2013 13
2014 14
2015 7
2016 11
2017 14
2018 12
2019 13
2020 13
2021 15
2022 21
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

288 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for murai a
Search for Murac A instead (2 results)
GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T. Miyata H, et al. Among authors: murai a. Cancer Immunol Immunother. 2022 Apr;71(4):795-806. doi: 10.1007/s00262-021-03025-z. Epub 2021 Aug 18. Cancer Immunol Immunother. 2022. PMID: 34405274 Free PMC article.
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Yamada S, et al. Among authors: murai a. Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 10.1007/s00262-023-03388-5. Epub 2023 Feb 16. Cancer Immunol Immunother. 2023. PMID: 36795123 Free PMC article.
Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma.
Matsuki M, Hirohashi Y, Nakatsugawa M, Murai A, Kubo T, Hashimoto S, Tokita S, Murata K, Kanaseki T, Tsukahara T, Nishida S, Tanaka T, Kitamura H, Masumori N, Torigoe T. Matsuki M, et al. Among authors: murai a. Cancer Immunol Immunother. 2022 Apr;71(4):905-918. doi: 10.1007/s00262-021-03048-6. Epub 2021 Sep 7. Cancer Immunol Immunother. 2022. PMID: 34491407 Free PMC article.
Exploring olfactory receptor family 7 subfamily C member 1 as a novel oral cancer stem cell target for immunotherapy.
Miyamoto S, Hirohashi Y, Morita R, Miyazaki A, Ogi K, Kanaseki T, Ide K, Shirakawa J, Tsukahara T, Murai A, Sasaya T, Koike K, Kina S, Kawano T, Goto T, Ntege EH, Shimizu Y, Torigoe T. Miyamoto S, et al. Among authors: murai a. Cancer Sci. 2023 Sep;114(9):3496-3508. doi: 10.1111/cas.15873. Epub 2023 Jun 21. Cancer Sci. 2023. PMID: 37344992 Free PMC article.
288 results